| scholarly article | Q13442814 |
| P50 | author | Elaine Mardis | Q5353251 |
| Obi Griffith | Q30503239 | ||
| Malachi Griffith | Q37382147 | ||
| Christopher A. Miller | Q41044336 | ||
| Timothy A. Graubert | Q55130327 | ||
| Catrina Fronick | Q63234110 | ||
| Jacqueline E Payton | Q89209245 | ||
| Lukas D Wartman | Q89282179 | ||
| Jasreet Hundal | Q90227995 | ||
| Jack Baty | Q117256852 | ||
| Tamara L Lamprecht | Q125342276 | ||
| P2093 | author name string | Richard K Wilson | |
| Vincent Magrini | |||
| Bradley A Ozenberger | |||
| Dong Shen | |||
| Timothy J Ley | |||
| David E Larson | |||
| David H Spencer | |||
| Eric J Duncavage | |||
| Shashikant Kulkarni | |||
| Jeffery M Klco | |||
| John F DiPersio | |||
| Matthew J Walter | |||
| Daniel C Link | |||
| Peter Westervelt | |||
| Robert Fulton | |||
| Jerald P Radich | |||
| Ryan T Demeter | |||
| Gue Su Chang | |||
| Michelle O'Laughlin | |||
| John S Welch | |||
| Matthew Christopher | |||
| Sharon E Heath | |||
| Nicole M Helton | |||
| Allegra Petti | |||
| Shamika Ketkar-Kulkarni | |||
| P2860 | cites work | PLINK: a tool set for whole-genome association and population-based linkage analyses | Q24677407 |
| AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation | Q24681049 | ||
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| Prognostic relevance of integrated genetic profiling in acute myeloid leukemia | Q27851726 | ||
| edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence | Q28385712 | ||
| Age-related clonal hematopoiesis associated with adverse outcomes | Q28386602 | ||
| Age-related mutations associated with clonal hematopoietic expansion and malignancies | Q28387160 | ||
| Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing | Q29614647 | ||
| Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 | ||
| Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy | Q33392185 | ||
| Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study | Q33770347 | ||
| Minimal residual disease in acute myeloid leukaemia | Q34179265 | ||
| Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis | Q34301317 | ||
| Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia | Q34403931 | ||
| Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission | Q34405195 | ||
| High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study | Q34996058 | ||
| Acute myeloid leukemia ontogeny is defined by distinct somatic mutations | Q35126237 | ||
| Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment | Q35565648 | ||
| Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. | Q36194222 | ||
| Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia | Q36290737 | ||
| Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group | Q36593525 | ||
| Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation | Q36920398 | ||
| Functional heterogeneity of genetically defined subclones in acute myeloid leukemia | Q37698123 | ||
| Minimal residual disease in acute myeloid leukemia: coming of age. | Q38066840 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia | Q41320689 | ||
| Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients | Q44467514 | ||
| Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. | Q50963749 | ||
| Persistence ofDNMT3Amutations at long-term remission in adult patients with AML | Q59194206 | ||
| Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461 | Q59315424 | ||
| Prognostic index for adult patients with acute myeloid leukemia in first relapse | Q81230380 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 811-822 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia | |
| P478 | volume | 314 |
| Q50538514 | A 17-gene stemness score for rapid determination of risk in acute leukaemia. |
| Q41182592 | A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy |
| Q27321277 | A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia |
| Q58611495 | A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data |
| Q92624250 | A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing |
| Q42665076 | A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML. |
| Q61803922 | A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia |
| Q92444544 | Acute Myeloid Leukemia: Aging and Epigenetics |
| Q38948650 | Acute Myeloid Leukemia: How Do We Measure Success? |
| Q58564462 | Acute Myeloid Leukemia: Is That All There Is? |
| Q90760094 | Acute myeloid leukaemia |
| Q47432401 | Acute myeloid leukaemia. |
| Q36849666 | Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification |
| Q38897289 | Acute myeloid leukemia: 2016 Update on risk-stratification and management |
| Q50020680 | Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. |
| Q104079538 | Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing |
| Q42360040 | Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer |
| Q39071892 | Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. |
| Q39132424 | Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. |
| Q48183562 | Can exome scans be expected to be part of real-time decision-making in patients with haematological cancers? |
| Q33822055 | Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). |
| Q95260253 | Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort |
| Q88493206 | Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia |
| Q42705413 | Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. |
| Q90036340 | Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation |
| Q92044405 | Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia |
| Q55279705 | Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. |
| Q93073300 | Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial |
| Q92787895 | Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications |
| Q53765401 | Comment on: Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. |
| Q30244036 | Current Management of Childhood Acute Myeloid Leukemia |
| Q50090381 | Cytarabine and daunorubicin for the treatment of acute myeloid leukemia |
| Q48255315 | DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. |
| Q39047646 | DNMT3A in Leukemia. |
| Q37624593 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel |
| Q48034587 | Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD. |
| Q41974114 | Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy |
| Q90237277 | Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms |
| Q39285841 | Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making |
| Q52632729 | Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. |
| Q89081092 | Evaluating measurable residual disease in acute myeloid leukemia |
| Q37318667 | Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease |
| Q60920843 | Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease |
| Q91559612 | Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia |
| Q27853389 | Genomic Classification and Prognosis in Acute Myeloid Leukemia |
| Q42322251 | Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing |
| Q40526958 | Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia |
| Q86085614 | Haematological cancer: Improving prediction of relapse risk |
| Q47134051 | Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies |
| Q91621196 | How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? |
| Q89426657 | How many cycles of 7+3 and for whom? |
| Q58090101 | Immune Escape of Relapsed AML Cells after Allogeneic Transplantation |
| Q38662892 | Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing |
| Q45886072 | Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia |
| Q37141503 | Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia |
| Q48186198 | Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia |
| Q88137948 | Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow |
| Q39208298 | Leukemic stem cells: identification and clinical application |
| Q50066248 | MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. |
| Q92512942 | MRD in AML: The Role of New Techniques |
| Q30234914 | Measurable residual disease testing in acute myeloid leukaemia. |
| Q50075132 | Measurement of Residual Disease in Acute Myeloid Leukemia |
| Q46113055 | Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. |
| Q47862030 | Methods of Detection of Measurable Residual Disease in AML. |
| Q92662026 | Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies |
| Q38749564 | Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group |
| Q39097771 | Minimal Residual Disease in Acute Myeloid Leukemia |
| Q58607135 | Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives |
| Q92611548 | Molecular MRD status and outcome after transplantation in NPM1-mutated AML |
| Q61448154 | Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response |
| Q91260564 | Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia |
| Q26776393 | Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance |
| Q42711146 | Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation |
| Q89828402 | Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia |
| Q47370037 | Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. |
| Q52803473 | Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. |
| Q64062942 | Mutational spectrum and associations with clinical features in patients with acute myeloid leukaemia based on next‑generation sequencing |
| Q94588308 | Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia |
| Q42637732 | New drug approvals in acute myeloid leukemia: what's the best end point? |
| Q64118224 | Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? |
| Q88796496 | Next-generation sequencing for measuring minimal residual disease in AML |
| Q64074899 | Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia |
| Q37559783 | Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). |
| Q89497134 | Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients |
| Q50642627 | Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing. |
| Q37338371 | Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia |
| Q52689074 | Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. |
| Q37072126 | Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia |
| Q38902497 | Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia |
| Q36934758 | Precision medicine for acute myeloid leukemia |
| Q38810911 | Precision medicine in pediatric oncology: Lessons learned and next steps |
| Q37683379 | Preleukemia: one name, many meanings |
| Q47128550 | Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia |
| Q55059516 | Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation. |
| Q39329093 | Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention |
| Q40370775 | Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation |
| Q102152194 | RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia |
| Q36596887 | Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. |
| Q86856819 | Recurrence, poor survival more likely in patients with acute myeloid leukemia who have certain mutations |
| Q60917013 | Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment |
| Q48272510 | Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. |
| Q61133296 | Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells |
| Q89291960 | Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia |
| Q95841350 | Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia |
| Q90160301 | Single-cell mutational profiling enhances the clinical evaluation of AML MRD |
| Q104073509 | Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells |
| Q30244244 | Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review |
| Q37566878 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes |
| Q59342678 | Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia |
| Q37568445 | Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome |
| Q41674738 | Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia. |
| Q59126923 | The Cooperative Relationship between STAT5 and Reactive Oxygen Species in Leukemia: Mechanism and Therapeutic Potential |
| Q47804815 | The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia. |
| Q38406756 | The clonal origins of leukemic progression of myelodysplasia |
| Q55243436 | The future of cancer treatment using precision oncogenomics. |
| Q33796552 | The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia |
| Q47099740 | The genomic landscape of pediatric myelodysplastic syndromes. |
| Q48121335 | The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. |
| Q47561008 | The rocky road to personalized medicine in acute myeloid leukaemia. |
| Q28071318 | Therapy-related myeloid neoplasms - what have we learned so far? |
| Q90460345 | Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial |
| Q90029210 | Treatments targeting MDS genetics: a fool's errand? |
| Q47109503 | Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
| Q40497621 | Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse |
| Q89459516 | Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy |
| Q59133388 | When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter |
| Q90028979 | When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter |
| Q59333333 | mutated AML can relapse with wild-type : persistent clonal hematopoiesis can drive relapse |
Search more.